Trial Profile
A Phase II, Open Label Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Advanced Unresectable/Metastatic Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Antibody Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Domatinostat (Primary)
- Indications Merkel cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms MERKLIN 2
- Sponsors 4SC AG
- 21 Mar 2024 This trial has been completed in France according to European Clinical Trials Database record.
- 12 Jul 2023 Planned End Date changed from 1 Mar 2025 to 1 Dec 2024.
- 12 Jul 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Feb 2024.